0
A complete range of cross-linked hyaluronic acid dermal fillers for superficial wrinkles, lip enhancement, midface volume enhancement and facial contouring.
For superficial to moderate facial wrinkles, lip contouring and augmentation. Contains 24 mg/mL hyaluronic acid with 3 mg/mL lidocaine; supplied in a 1 mL syringe with a 25 G needle and a stated duration of 9–12 months.
View ProductFor superficial wrinkles and fine lines. Contains 24 mg/mL hyaluronic acid with 3 mg/mL lidocaine; supplied in a 1 mL syringe with a 27 G needle and a stated duration of 9–12 months.
View ProductFor deep facial wrinkles and folds, midface volume enhancement and facial contouring. Contains 24 mg/mL hyaluronic acid with 3 mg/mL lidocaine; supplied in a 1 mL syringe with a 25 G needle and a stated duration of 12 months.
View Product
BDDE is one of the most widely used cross-linking agents in HA dermal fillers. Understanding its role, the cross-linking reaction and control of residual BDDE is an important part of understanding filler manufacturing and quality.
The physical structure of an HA filler can influence its rheological behavior, injectability and interaction with tissue. Particle or gel-structure characteristics are therefore relevant considerations in filler formulation and manufacturing.
The quality of an HA dermal filler depends on multiple factors extending from the starting HA material to cross-linking, purification, formulation, filling and final quality control.
PERSIFILL® is a range of cross-linked hyaluronic acid dermal fillers designed for different facial aesthetic applications, including wrinkle correction, lip enhancement, volume restoration and facial contouring.
PERSIFILL® is formulated with 24 mg/mL of hyaluronic acid cross-linked with BDDE. The products also contain 3 mg/mL lidocaine to help enhance patient comfort during the injection procedure.
Although all three products contain 24 mg/mL of hyaluronic acid, they differ in their degree of cross-linking and rheological properties. PERSIFILL® Soft is formulated for superficial wrinkles and fine lines, PERSIFILL® Mild is designed for superficial to moderate wrinkles as well as lip contouring and augmentation, while PERSIFILL® Hard is intended for deep wrinkles and folds, midface volume enhancement and facial contouring. Product selection should consider the treatment area, tissue depth and desired level of correction.
The stated duration of PERSIFILL® is 9-12 months. Actual duration may vary depending on the treatment area, injection technique, product selection and individual patient characteristics.
Yes. PERSIFILL® contains 3 mg/mL lidocaine, incorporated into the formulation to help improve patient comfort during the injection procedure.
PERSIFILL® uses BDDE (1,4-butanediol diglycidyl ether) as the cross-linking agent.
PERSIFILL® is manufactured under quality control processes that comply with international standards, including KGMP and ISO 13485. Applicable products and components carry the CE Mark in accordance with relevant European requirements.
Product selection should be based on the treatment indication, anatomical area, tissue depth, desired level of correction and individual patient assessment. The treating physician should determine the most appropriate product and injection technique based on clinical judgment.
The desired correction and volume enhancement may be visible immediately, although the final appearance may vary depending on the treatment area, injection technique and individual patient characteristics. Temporary reactions such as redness, swelling, tenderness, bruising or itching may occur at the injection site. Patients should follow the post-treatment recommendations provided by their healthcare professional.
As a hyaluronic acid-based dermal filler, PERSIFILL® may be enzymatically degraded using hyaluronidase when clinically indicated. Any decision regarding hyaluronidase should be made by an appropriately qualified healthcare professional based on the individual clinical circumstances.
The duration of PERSIFILL® results is stated as 9-12 months. Actual longevity may vary according to the treatment area, product selection, injection technique, individual patient characteristics, tissue characteristics and metabolic factors.
The suitability of combining PERSIFILL® with other aesthetic treatments depends on the treatment area, the products or procedures involved and the individual patient. Treatment planning and sequencing should be determined by an appropriately qualified healthcare professional following an assessment.
PERSIFILL® should be administered only by appropriately qualified healthcare professionals who have the necessary training, experience and knowledge of facial anatomy and injectable aesthetic procedures. Treatment should be performed in accordance with the product's approved indications, instructions for use and applicable local regulations.
